GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tango Therapeutics Inc (NAS:TNGX) » Definitions » Change In Payables And Accrued Expense

Tango Therapeutics (Tango Therapeutics) Change In Payables And Accrued Expense : $0.85 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Tango Therapeutics Change In Payables And Accrued Expense?

Tango Therapeutics's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was $-0.57 Mil. It means Tango Therapeutics's Accounts Payable & Accrued Expense declined by $0.57 Mil from Dec. 2023 to Mar. 2024 .

Tango Therapeutics's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was $-3.73 Mil. It means Tango Therapeutics's Accounts Payable & Accrued Expense declined by $3.73 Mil from Dec. 2022 to Dec. 2023 .


Tango Therapeutics Change In Payables And Accrued Expense Historical Data

The historical data trend for Tango Therapeutics's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tango Therapeutics Change In Payables And Accrued Expense Chart

Tango Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Change In Payables And Accrued Expense
2.37 5.06 8.73 -3.73

Tango Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Payables And Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.15 1.25 -3.74 3.91 -0.57

Tango Therapeutics Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.85 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tango Therapeutics Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Tango Therapeutics's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Tango Therapeutics (Tango Therapeutics) Business Description

Industry
Traded in Other Exchanges
N/A
Address
201 Brookline Avenue, Suite 901, Boston, MA, USA, 02215
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies.
Executives
Adam Crystal officer: See Remarks C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Boxer Capital, Llc other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
John B Ketchum director TANGO THERAPEUTICS, INC., 201 BROOKLINE AVE., SUITE 901, BOSTON MA 02215
Joseph Lewis other: See remarks PO BOX N7776, LYFORD BAHAMAS
Trv Gp Vi, Llc director 201 BROOKLINE AVE., BOSTON MA 02215
Third Rock Ventures Gp Vi, L.p. director 201 BROOKLINE AVE, SUITE 1401, BOSTON MA 02215
Third Rock Ventures Vi, L.p. director 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Aaron I. Davis other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Boxer Asset Management Inc. other: See remarks CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Mva Investors, Llc other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Aaron Weitzman officer: Chief Medical Officer TANGO THERAPEUTICS, INC., 201 BROOKLINE AVE., SUITE 901, BOSTON MA 02215
Marc Rudoltz officer: Chief Medical Officer TANGO THERAPEUTICS, INC., 100 BINNEY STREET, UNIT 700, CAMBRIDGE MA 02142
Douglas Barry officer: See Remarks TANGO THERAPEUTICS, INC., 100 BINNEY STREET, UNIT 700, CAMBRIDGE MA 02142
Third Rock Ventures Iv, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116